Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction

Georg Griesinger, Herman Tournaye, Nick Macklon, Felice Petraglia, Petra Arck, Christophe Blockeel, Peter van Amsterdam, Claire Pexman-Fieth, Bart Cjm Fauser

Onderzoeksoutput: Scientific review

21 Citaten (Scopus)


The pharmacological and physiological profiles of progestogens used for luteal phase support during assisted reproductive technology are likely to be important in guiding clinical choice towards the most appropriate treatment option. Various micronized progesterone formulations with differing pharmacological profiles have been investigated for several purposes. Dydrogesterone, a stereoisomer of progesterone, is available in an oral form with high oral bioavailability; it has been used to treat a variety of conditions related to progesterone deficiency since the 1960s and has recently been approved for luteal phase support as part of an assisted reproductive technology treatment. The primary objective of this review is to critically analyse the clinical implications of the pharmacological and physiological properties of dydrogesterone for its uses in luteal phase support and in early pregnancy.

Originele taal-2English
Pagina's (van-tot)249-259
Aantal pagina's11
TijdschriftReproductive BioMedicine Online
Nummer van het tijdschrift2
StatusPublished - feb 2019

Bibliografische nota

Copyright © 2018 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.


Duik in de onderzoeksthema's van 'Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction'. Samen vormen ze een unieke vingerafdruk.

Citeer dit